Before the development of highly specific tyrosine kinase inhibitors (TKI) against BCR-ABL, CML was a life-threatening disease and can today be controlled with a life expectancy close to normal. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.